COVID-19患者血清尿酸水平、疾病严重程度与结局
在比利时布鲁塞尔一家大型学术医院开展回顾性研究,采用发现队列(192例)与验证队列(325例)共517例住院COVID-19患者,评估低尿酸血症的患病率、动态变化及临床相关性。低尿酸血症患病率从入院时6%升至住院最初数天的20%,而COVID-19住院前发生率<1%。中位随访148天(IQR 50-168)期间,61例(12%)需机械通气、93例(18%)死亡;低血清尿酸水平与疾病严重程度(线性趋势P<0.001)及进展至死亡和需机械通气的呼吸衰竭相关(Cox模型校正HR 5.3,95%CI 3.6-7.8,P<0.001;竞争风险模型校正HR 20.8,95%CI 10.4-41.4,P<0.001)。肾脏近端小管刷状缘尿酸转运体URAT1表达显著降低。
要点
- 住院COVID-19患者低尿酸血症患病率从入院时6%升至住院最初数天的20%,住院前发生<1%。
- 低血清尿酸水平与疾病严重程度相关(线性趋势P<0.001),两个队列分别分析及汇总分析结果一致。
- 中位随访148天(IQR 50-168)内61例(12%)需机械通气、93例(18%)死亡。
- 低尿酸水平与进展至死亡和需机械通气的呼吸衰竭相关:Cox模型校正HR 5.3(95%CI 3.6-7.8,P<0.001),竞争风险模型校正HR 20.8(95%CI 10.4-41.4,P<0.001)。
- COVID-19死亡患者肾近端小管刷状缘尿酸转运体URAT1表达显著降低。
适用人群与场景
- 比利时布鲁塞尔一家大型学术医院住院的COVID-19患者,发现队列192例、验证队列325例,共517例;其中274例(53%)为重症、92例(18%)为危重症COVID-19。
研究设计与关键结果
- 研究类型:回顾性研究,使用两个独立队列(发现队列与验证队列),在比利时布鲁塞尔一家大型学术医院住院的COVID-19患者中调查并验证低尿酸血症的患病率、动态变化及临床相关性。
- 人群与样本量:发现队列192例、验证队列325例,共517例住院COVID-19患者;274例(53%)为重症、92例(18%)为危重症。
- 低尿酸血症患病率:两个队列中均从入院时6%升至住院最初数天的20%,而COVID-19住院前发生率<1%。
- 随访与结局:中位随访148天(IQR 50-168),61例(12%)需机械通气、93例(18%)死亡。
- 主要关联:两个队列分别分析及汇总分析中,低血清尿酸水平与疾病严重程度强烈相关(线性趋势P<0.001)。
- 生存分析:低血清尿酸水平与进展至死亡和需机械通气的呼吸衰竭相关,Cox模型校正HR 5.3(95%CI 3.6-7.8,P<0.001),竞争风险模型校正HR 20.8(95%CI 10.4-41.4,P<0.001)。
- 机制层面:COVID-19死亡患者肾脏近端小管刷状缘尿酸转运体URAT1表达显著降低。
证据类型、等级与局限
- 证据类型:回顾性研究,使用两个独立队列(发现队列与验证队列)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在需住院的COVID-19患者中,低血清尿酸水平常见,并与疾病严重程度及进展至需有创机械通气的呼吸衰竭相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The severity of coronavirus disease 2019 (COVID-19) is highly variable between individuals, ranging from asymptomatic infection to critical disease with acute respiratory distress syndrome requiring mechanical ventilation. Such variability stresses the need for novel biomarkers associated with disease outcome. As SARS-CoV-2 infection causes a kidney proximal tubule dysfunction with urinary loss of uric acid, we hypothesized that low serum levels of uric acid (hypouricemia) may be associated with severity and outcome of COVID-19.
METHODS: In a retrospective study using two independent cohorts, we investigated and validated the prevalence, kinetics and clinical correlates of hypouricemia among patients hospitalized with COVID-19 to a large academic hospital in Brussels, Belgium. Survival analyses using Cox regression and a competing risk approach assessed the time to mechanical ventilation and/or death. Confocal microscopy assessed the expression of urate transporter URAT1 in kidney proximal tubule cells from patients who died from COVID-19.
RESULTS: The discovery and validation cohorts included 192 and 325 patients hospitalized with COVID-19, respectively. Out of the 517 patients, 274 (53%) had severe and 92 (18%) critical COVID-19. In both cohorts, the prevalence of hypouricemia increased from 6% upon admission to 20% within the first days of hospitalization for COVID-19, contrasting with a very rare occurrence (< 1%) before hospitalization for COVID-19. During a median (interquartile range) follow-up of 148 days (50-168), 61 (12%) patients required mechanical ventilation and 93 (18%) died. In both cohorts considered separately and in pooled analyses, low serum levels of uric acid were strongly associated with disease severity (linear trend, P < 0.001) and with progression to death and respiratory failure requiring mechanical ventilation in Cox (adjusted hazard ratio 5.3, 95% confidence interval 3.6-7.8, P < 0.001) or competing risks (adjusted hazard ratio 20.8, 95% confidence interval 10.4-41.4, P < 0.001) models. At the structural level, kidneys from patients with COVID-19 showed a major reduction in urate transporter URAT1 expression in the brush border of proximal tubules.
CONCLUSIONS: Among patients with COVID-19 requiring hospitalization, low serum levels of uric acid are common and associate with disease severity and with progression to respiratory failure requiring invasive mechanical ventilation.
参考来源
- Dufour I, Werion A, Belkhir L, et al. Serum uric acid, disease severity and outcomes in COVID-19. Crit Care. 2021. PMID: 34127048. doi:10.1186/s13054-021-03616-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。